Lynn Anne Bristol

Array ( [id] => 15527259 [patent_doc_number] => 20200055935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => Anti-TIM-3 Antibodies [patent_app_type] => utility [patent_app_number] => 16/551944 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15620 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16551944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15436125 [patent_doc_number] => 20200032246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/533864 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15563921 [patent_doc_number] => 20200066372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => METHOD FOR IMPROVING ANTIBODY STABILITY [patent_app_type] => utility [patent_app_number] => 16/530375 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15147877 [patent_doc_number] => 20190352416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => TRISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/530946 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16530946 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293667 [patent_doc_number] => 20190389969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => NTRK2 FUSIONS [patent_app_type] => utility [patent_app_number] => 16/529244 [patent_app_country] => US [patent_app_date] => 2019-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13699 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16529244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711275 [patent_doc_number] => 20200102403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS [patent_app_type] => utility [patent_app_number] => 16/512672 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16512672 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086411 [patent_doc_number] => 20190338016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => Therapeutic Biologic for Treatment of Hepatocellular Carcinoma [patent_app_type] => utility [patent_app_number] => 16/513148 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513148 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824299 [patent_doc_number] => 20210139592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => ANTI-HUMAN PD-L1 ANTIBODIES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 17/256999 [patent_app_country] => US [patent_app_date] => 2019-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15324193 [patent_doc_number] => 20200002426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => ANTITUMOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/457399 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30855 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16457399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293657 [patent_doc_number] => 20190389964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => HUMANIZED ANTIBODIES THAT BIND LGR5 [patent_app_type] => utility [patent_app_number] => 16/449154 [patent_app_country] => US [patent_app_date] => 2019-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16449154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19360885 [patent_doc_number] => 20240262919 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => HUMAN ANTIBODIES TO HUMAN INTERLEUKIN 18 RECEPTOR ALPHA AND BETA [patent_app_type] => utility [patent_app_number] => 17/254248 [patent_app_country] => US [patent_app_date] => 2019-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17254248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314507 [patent_doc_number] => 20210403555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ANTI-PODOPLANIN ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/626162 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052225 [patent_doc_number] => 20210261659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => CD79A CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/973879 [patent_app_country] => US [patent_app_date] => 2019-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16973879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18172716 [patent_doc_number] => 11572413 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers [patent_app_type] => utility [patent_app_number] => 16/438886 [patent_app_country] => US [patent_app_date] => 2019-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25471 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438886 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15267523 [patent_doc_number] => 20190382495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/435373 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15293637 [patent_doc_number] => 20190389954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/435375 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52626 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15290671 [patent_doc_number] => 20190388471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 16/435257 [patent_app_country] => US [patent_app_date] => 2019-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 107140 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16435257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977678 [patent_doc_number] => 20210221915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => UNIVERSAL OR NORMALIZED ANTIBODY FRAMEWORKS FOR IMPROVED FUNCTIONALITY AND MANUFACTURABILITY [patent_app_type] => utility [patent_app_number] => 15/734301 [patent_app_country] => US [patent_app_date] => 2019-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734301 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990260 [patent_doc_number] => 20210228680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VERSUS HOST DISEASE AND MUCOSITIS [patent_app_type] => utility [patent_app_number] => 15/734961 [patent_app_country] => US [patent_app_date] => 2019-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800219 [patent_doc_number] => 20200123252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47 [patent_app_type] => utility [patent_app_number] => 16/428539 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -150 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16428539 [rel_patent_id] =>[rel_patent_doc_number] =>)